TICKERNOMICS Sign up
Last Update: 2024-03-28 02:15:56
Cyclacel Pharmaceuticals Inc. ( CYCC ) https://www.cyclacel.com
1.92USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-77.54%
CYCC
SPY
32.74%
-98.27%
CYCC
SPY
92.93%
-99.32%
CYCC
SPY
224.41%
-99.98%
CYCC
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
2.31
-1.09
0.11
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.09
3.35
3.80
-9.74
0.00
0.04
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-42781.25
100.00
-6423.52
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.627
-238.47
-263.87
0.90
Other Earnings and Cash Flow Stats:
Cyclacel Pharmaceuticals Inc. ( CYCC ) Net Income TTM ($MM) is -24.42
Cyclacel Pharmaceuticals Inc. ( CYCC ) Operating Income TTM ($MM) is -29.48
Cyclacel Pharmaceuticals Inc. ( CYCC ) Owners' Earnings Annual ($MM) is -20.31
Cyclacel Pharmaceuticals Inc. ( CYCC ) Current Price to Owners' Earnings ratio is -0.10
Cyclacel Pharmaceuticals Inc. ( CYCC ) EBITDA TTM ($MM) is -29.66
Cyclacel Pharmaceuticals Inc. ( CYCC ) EBITDA Margin is -6423.52%
Capital Allocation:
Cyclacel Pharmaceuticals Inc. ( CYCC ) has paid 0.00 dividends per share and bought back 10.196785 million shares in the past 12 months
Cyclacel Pharmaceuticals Inc. ( CYCC ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Cyclacel Pharmaceuticals Inc. ( CYCC ) Interest-bearing Debt ($MM) as of last quarter is 0
Cyclacel Pharmaceuticals Inc. ( CYCC ) Annual Working Capital Investments ($MM) are -2
Cyclacel Pharmaceuticals Inc. ( CYCC ) Book Value ($MM) as of last quarter is 0
Cyclacel Pharmaceuticals Inc. ( CYCC ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Cyclacel Pharmaceuticals Inc. ( CYCC ) has 3 million in cash on hand as of last quarter
Cyclacel Pharmaceuticals Inc. ( CYCC ) has 8 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Cyclacel Pharmaceuticals Inc. ( CYCC ) has 1 common shares outstanding as of last quarter
Cyclacel Pharmaceuticals Inc. ( CYCC ) has 0 million USD of preferred stock value
Academic Scores:
Cyclacel Pharmaceuticals Inc. ( CYCC ) Altman Z-Score is -78.07 as of last quarter
Cyclacel Pharmaceuticals Inc. ( CYCC ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Cyclacel Pharmaceuticals Inc. ( CYCC ) largest shareholder is owning shares at 0.00 ($MM) value
Spiro George Rombotis(an insider) Bought 6070 shares of Cyclacel Pharmaceuticals Inc. ( CYCC ) for the amount of $20091.70 on 2023-12-21
7.04% of Cyclacel Pharmaceuticals Inc. ( CYCC ) is held by insiders, and 33.04% is held by institutions
Cyclacel Pharmaceuticals Inc. ( CYCC ) went public on 2004-05-05
Other Cyclacel Pharmaceuticals Inc. ( CYCC ) financial metrics:
FCF:-15.37
Unlevered Free Cash Flow:-21.43
EPS:-23.03
Operating Margin:-42781.25
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-4017.79
Beta:0.90
Buffet's Owners Earnings:-20.31
Price to Owner's Earnings:-0.10
About Cyclacel Pharmaceuticals Inc. ( CYCC ) :
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company is headquartered in Berkeley Heights, New Jersey
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.